武漢佰樂博代理：Research Grade Tebentafusp

貨號:DHC27706

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75404.html

產(chǎn)品購買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Tebentafusp (IMCgp100)是一種雙特異性融合蛋白，靶向gp100 (一種黑色素瘤相關(guān)抗原)。Tebentafusp通過高親和力T細(xì)胞受體(TCR)結(jié)合域和抗CD3 T細(xì)胞接合域引導(dǎo)T細(xì)胞殺死表達(dá)gp100的腫瘤細(xì)胞。Tebentafusp誘導(dǎo)炎性細(xì)胞因子和細(xì)胞溶解蛋白的產(chǎn)生，導(dǎo)致腫瘤細(xì)胞的直接裂解。

通用名:Tebentafusp

純度:>95% by SDS-PAGE.

濃度:1mg/ml

Formulationicon:0.01M PBS, pH 7.4.

內(nèi)毒素:Please contact with the lab for this information.

別名:Bispecific fusion protein

靶點;物種:Human CD3E & TCR

種類:Humanized

受體鑒定:scFv-TR-BETA

CAS: 1874157-95-5

參考文獻(xiàn)：

Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. PMID: 35060440

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. PMID: 35254876

Antibodies to watch in 2022. PMID: 35030985

Tebentafusp for uveal melanoma. PMID: 34625736

Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. PMID: 36970111

Uveal melanoma. PMID: 32273508

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma. PMID: 36847626

Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma. PMID: 36199496

Tebentafusp in first-line melanoma trials: An outperforming outlier. PMID: 35364557

Antibodies to watch in 2023. PMID: 36472472

Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations. PMID: 36785760

Metastatic uveal melanoma: The final frontier. PMID: 34999237

T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. PMID: 35880455

Tebentafusp als neuartige Immuntherapie zeigt einen überlebensvorteil beim metastasierten Uveamelanom und wird bereits in Deutschland eingesetzt. PMID: 35304951

A review of the cutaneous toxicities of tebentafusp-Featuring two cases involving superficial bullous reactions. PMID: 35510367

Advances in the clinical management of uveal melanoma. PMID: 36600005

Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. PMID: 36931146

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. PMID: 37286303

Recent Advances and Challenges in Uveal Melanoma Immunotherapy. PMID: 35804863

Drug-induced photosensitivity during tebentafusp treatment for metastatic uveal melanoma: A newly described occurrence. PMID: 36177547

[New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients]. PMID: 36357199

Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. PMID: 34885078

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report. PMID: 37207136

Review of bi-specific therapies in uveal melanoma. PMID: 35236927

Evolving Management of Stage IV Melanoma. PMID: 37141553

TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma. PMID: 35267523

First Drug Approved for Rare Eye Cancer. PMID: 35115315

Immunotherapies for the Treatment of Uveal Melanoma-History and Future. PMID: 31344957

Novel Approaches to the Systemic Management of Uveal Melanoma. PMID: 32725406

Combination strategies to durably suppress HIV-1: Soluble T cell receptors. PMID: 36065296

T cell engagers in solid tumors kick the door down. PMID: 34752755

Ensuring equity in the era of HLA-restricted cancer therapeutics. PMID: 36442912

Nail Apparatus Melanoma: Current Management and Future Perspectives. PMID: 36983205

TCR Bispecific Boosts Survival in Uveal Melanoma. PMID: 33839690

Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours. PMID: 31207478

Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis. PMID: 36094043

Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives. PMID: 34431316

Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. PMID: 36710368

Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors. PMID: 36255733

Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients. PMID: 36672442

Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review. PMID: 37350009

Immunotherapy for ocular melanoma: a bibliometric and visualization analysis from 1991 to 2022. PMID: 37324010

Determinants of overall survival in patients with metastatic uveal melanoma. PMID: 37382208